Inactive Instrument

News Amryt Pharma plc

Equities

AMYT

US03217L1061

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy	Feb. 05	AQ
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma	Nov. 10	AQ
Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	23-04-13	CI
2022 for Chiesi, The Group's international growth continues	23-04-12	AQ
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	23-04-12	GL
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	23-04-12	GL
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	23-04-12	CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others.	23-04-11	CI
2022 for Chiesi: The Group’s international growth continues	23-04-11	AQ
Amryt Pharma Plc - High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-04	AQ
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-03	GL
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-03	AQ
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici	23-03-22	MT
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici	23-03-22	GL
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired.	23-03-07	CI
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	23-02-24	BU
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	23-02-16	GL
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	23-02-16	AQ
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	23-01-10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amryt Pharma plc

Equities

AMYT

US03217L1061

Summary

Filters